Henry Schein (NASDAQ:HSIC) Announces Quarterly Earnings Results

Henry Schein (NASDAQ:HSIC) released its quarterly earnings data on Tuesday. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.20, Zacks reports. The firm had revenue of $3.47 billion during the quarter, compared to analyst estimates of $3.48 billion. Henry Schein had a return on equity of 16.39% and a net margin of 3.07%. The business’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.38 earnings per share.

Here are the key takeaways from Henry Schein’s conference call:

• U.S. dental merchandise sales rose 8.6%, including 7% internal local-currency growth, driven primarily by volume and claimed market-share gains among private practices and emerging DSOs.
• Adjusted non-GAAP diluted EPS increased 19.1% to $1.37, while non-GAAP operating margin expanded 20 basis points to 8.03%; management said its value-creation program remains on track to deliver more than $200 million of operating-income improvement, including a $125 million run rate by year-end 2026.
• Henry Schein raised 2026 non-GAAP EPS guidance to $5.50-$5.56 from $5.29-$5.39 and expects adjusted EBITDA growth in the high single digits, citing stronger underlying performance and a $0.19-per-share tariff-refund benefit.
• Management plans targeted fourth-quarter investments in customer acquisition, share of wallet, company-owned and exclusive products, and cloud-based practice-management software, while continuing share repurchases; it bought back $125 million of stock in the quarter and had approximately $330 million remaining under authorization.
• The U.S. dental market and patient traffic were described as stable, but discretionary procedures showed some pressure from out-of-pocket costs; medical growth was also restrained by weaker point-of-care diagnostic and flu/COVID vaccine demand, partly offset by 11.4% growth in Home Solutions.

Henry Schein Trading Down 3.7%

Shares of NASDAQ:HSIC traded down $3.27 on Thursday, hitting $84.97. The company had a trading volume of 710,582 shares, compared to its average volume of 1,347,754. The firm’s 50-day simple moving average is $86.32 and its two-hundred day simple moving average is $81.23. The firm has a market capitalization of $9.47 billion, a price-to-earnings ratio of 23.27, a P/E/G ratio of 1.44 and a beta of 0.87. The company has a quick ratio of 0.73, a current ratio of 1.33 and a debt-to-equity ratio of 0.62. Henry Schein has a 1 year low of $68.70 and a 1 year high of $92.18.

Analysts Set New Price Targets

HSIC has been the subject of several analyst reports. Citigroup reissued a “buy” rating and set a $112.00 price target (up from $100.00) on shares of Henry Schein in a research report on Wednesday, August 5th. Piper Sandler boosted their price objective on shares of Henry Schein from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Weiss Ratings raised shares of Henry Schein from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, August 21st. Barclays reiterated an “overweight” rating and set a $100.00 target price (up from $86.00) on shares of Henry Schein in a report on Thursday, August 6th. Finally, Leerink Partners set a $92.00 target price on Henry Schein and gave the stock a “market perform” rating in a research note on Wednesday, October 14th. Eight analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.57.

Key Stories Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Zacks upgraded Henry Schein to Rank #2 (Buy), citing improving earnings prospects—a potentially supportive near-term signal. Henry Schein upgraded to Buy
• Positive Sentiment: Third-quarter EPS of $1.56 beat the $1.36 consensus estimate, while revenue increased 4% year over year. A Q3 discussion also highlighted dental-volume gains, margin initiatives, and a tariff-refund benefit. Q3 results deep dive
• Neutral Sentiment: UBS lifted its price target from $94 to $95 but maintained a Neutral rating, indicating modestly higher valuation expectations without a stronger recommendation. UBS rating information
• Neutral Sentiment: Henry Schein confirmed its 2026 earnings guidance rather than raising it. The company also plans to participate in investor conferences in November and December. 2026 earnings guidance
• Negative Sentiment: Revenue of $3.47 billion was slightly below the $3.48 billion consensus estimate, a small shortfall that may temper the strong EPS beat. Q3 revenue results

About Henry Schein

Henry Schein, Inc (NASDAQ: HSIC) is a global provider of healthcare products and services serving dental and medical professionals, as well as veterinary practices and laboratories. The company distributes consumable supplies, equipment, pharmaceuticals, vaccines, and other products used in clinical and practice-management settings.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support clinical workflows, electronic health records, practice management, procurement, equipment installation, and technical support.